Core Viewpoint - The article highlights the significant innovations introduced by Bruker at the ASMS 2025 conference, particularly the launch of the timsOmni™, timsMetabo™, and proteoElute™ systems, which are expected to advance research in proteomics and metabolomics significantly [1][2][3]. Group A: timsOmni™ Mass Spectrometry System - The timsOmni™ system is a revolutionary mass spectrometry platform designed for in-depth analysis of biomolecular structures, particularly in the fields of scientific research, drug development, clinical studies, and biopharmaceutical quality control [3]. - It features a multi-modal eXd capture technology that allows precise electronic energy control, ion accumulation, and adjustable reaction times, supporting various fragmentation methods for comprehensive structural information [3][5]. - The system is particularly adept at identifying low-abundance protein variants associated with diseases such as cancer and neurodegenerative disorders, enhancing the understanding of protein function and pathology [5][7]. Group B: OmniScape™ Software - OmniScape™ is a new generation protein sequencing analysis software that supports data analysis from the timsOmni™ system, offering advanced algorithms for complex spectrum deconvolution and protein identification [5][9]. - It transforms complex eXd fragmentation spectra into biologically relevant information, facilitating the study of functional proteomics [5][9]. Group C: timsMetabo™ Mass Spectrometry System - The timsMetabo™ system is a high-performance 4D mass spectrometry instrument that enhances small molecule analysis and integrates seamlessly with high-sensitivity proteomics [10][12]. - It introduces the "MoRE" scanning mode, which significantly improves sensitivity, separation capability, and annotation reliability for metabolomics studies [12][14]. - The system generates unique digital metabolomic profiles for each sample, enhancing the reliability of analysis results and supporting AI applications in metabolomics [14]. Group D: proteoElute™ Nanoflow Liquid Chromatography System - The proteoElute™ system is designed to provide sensitive and robust solutions for proteomics, particularly in analyzing protein variants and complex biological samples [15][16]. - It features the TwinScape™ technology for real-time system monitoring and proactive maintenance, ensuring reliable performance even with low sample volumes [16]. - The new PepSep® Advanced chromatography column enhances peak shape and resolution, improving peptide and protein identification rates by approximately 20% and 10%, respectively [17].

Financial Data and Key Metrics Changes - The meeting confirmed that a quorum was present with over 95% of shares entitled to vote represented [3][4] - The compensation of $20.24 paid to named executive officers was approved by a non-binding advisory vote [10] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting Company Strategy and Development Direction and Industry Competition - The company proposed the adoption of the 2026 Incentive Compensation Plan, indicating a focus on aligning executive compensation with long-term performance [7][10] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for fiscal year 2025 was ratified [10] - Four Class I directors were elected to hold office until the 2028 Annual Meeting of Stockholders [10] Q&A Session All Questions and Answers - No questions were raised during the meeting, and the formal business concluded without further discussion [11][12]

Core Viewpoint - Bruker Corporation reported a strong Q1 2025 performance with an 11.0% revenue growth, but maintains a cautious outlook for the full year due to anticipated impacts from reduced U.S. research funding, estimating a revenue hit of $100 million [1][11]. Revenue Performance - Q1 2025 revenue reached $801.4 million, up from $721.7 million in Q1 2024, reflecting an 11.0% increase. Organic growth for the quarter was 2.9%, while revenue growth at constant exchange rates (CER) was 12.5% [3][6]. - The core business segment, Bruker BioSpin (BSI), generated $744.5 million in revenue, a 14.3% year-over-year increase, with organic growth of 5.1% [3][6]. - The BioSpin segment's revenue included $208 million from the BioSpin division, $280.1 million from the CALID division, and $256.6 million from the Nano division [6]. Segment Analysis - The CALID segment achieved $280.1 million in revenue, driven by significant growth in microbiology and molecular diagnostics, including contributions from the newly acquired LETEC [4][6]. - The Nano segment reported $256.6 million in revenue, with high single-digit growth attributed to non-organic growth from NanoString, despite weak performance in Europe and China [4][6]. - The BEST segment saw a revenue decline to $59.3 million, down 18.9% year-over-year, with organic revenue dropping 17.7% when excluding intercompany transactions [5][6]. Strategic Developments - Bruker launched several high-performance innovative products at key conferences in Q1, including NMR systems and platforms for microbiology and molecular diagnostics, enhancing its competitive position in multi-omics and spatial biology markets [6]. - The company completed a significant acquisition of Recipharm, entering the non-infectious disease diagnostics market, which aligns with its strategy in differentiated triple quadrupole mass spectrometry [9]. Full Year Outlook - For the full year 2025, Bruker expects revenue between $3.48 billion and $3.55 billion, representing a year-over-year growth of 3.5% to 5.5% [11][13]. - The company anticipates organic revenue growth of 0% to 2%, with acquisitions contributing approximately 2.5% to revenue growth and foreign exchange effects adding about 1% [13]. - Non-GAAP earnings per share are projected to be between $2.40 and $2.48, reflecting a slight increase compared to the previous year [13].

Project Overview - The procurement project is for the purchase of field emission scanning electron microscopes and other scientific equipment for Zhengzhou University, with a total bid amount of 29.28 million [2][3]. - The project includes multiple packages, such as field emission scanning electron microscopes, mass spectrometers, and liquid chromatography mass spectrometry systems [3]. Procurement Details - The procurement method used was open bidding, with the announcement published on April 14, 2025, and the evaluation date set for May 7, 2025 [3]. - The delivery period is 180 calendar days from the effective date of the contract, and the delivery location is designated by the purchaser [3]. Bidder Information - The winning bids include: - HITACHI for a field emission scanning electron microscope at a price of 6,695,000 CNY [4]. - Bruker for a mass spectrometer at a price of 6,480,000 CNY [4]. - SCIEX for a liquid chromatography mass spectrometry system at a price of 4,990,000 CNY [5]. - Thermo Fisher Scientific for another liquid chromatography mass spectrometry system at a price of 8,220,000 CNY [5]. Quality Assurance - The quality assurance periods vary by package, with the field emission scanning electron microscope having a 5-year warranty and the mass spectrometers and liquid chromatography systems having a 3-year warranty [3].

Part I [Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201%3A%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section presents Bruker Corporation's unaudited financial statements for Q1 2025, including balance sheets, income statements, and cash flows, with notes on accounting policies and key events [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets increased to $5.93 billion from $5.81 billion at year-end 2024, driven by higher inventories and other assets, while total liabilities rose to $4.08 billion from $3.98 billion, primarily due to increases in deferred revenue and other current liabilities, and total shareholders' equity grew to $1.83 billion Condensed Consolidated Balance Sheet Data (in millions) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Assets** | **$5,933.1** | **$5,806.7** | | Total Current Assets | $2,111.5 | $2,053.2 | | Goodwill and intangible assets, net | $2,434.6 | $2,419.8 | | **Total Liabilities** | **$4,081.9** | **$3,991.5** | | Total Current Liabilities | $1,344.9 | $1,281.3 | | Long-term debt | $2,076.1 | $2,061.8 | | **Total Shareholders' Equity** | **$1,832.9** | **$1,797.1** | [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) For the first quarter of 2025, total revenue increased by 11.0% year-over-year to $801.4 million, but operating income fell significantly to $31.8 million from $64.8 million in Q1 2024, largely due to higher operating expenses, resulting in net income attributable to Bruker Corporation decreasing to $17.4 million, or $0.11 per diluted share Q1 2025 vs. Q1 2024 Statement of Operations (in millions, except per share data) | Metric | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Total Revenue | $801.4 | $721.7 | 11.0% | | Gross Profit | $391.2 | $352.8 | 10.9% | | Operating Income | $31.8 | $64.8 | (50.9)% | | Net Income Attributable to Bruker | $17.4 | $50.9 | (65.8)% | | Diluted EPS | $0.11 | $0.35 | (68.6)% | [Unaudited Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, net cash provided by operating activities significantly improved to $65.0 million from $21.8 million in Q1 2024, while net cash used in investing activities decreased sharply to $26.1 million from $304.2 million, and financing activities used $51.2 million in cash, a reversal from the $151.7 million provided in the prior-year quarter Cash Flow Summary (in millions) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $65.0 | $21.8 | | Net cash used in investing activities | $(26.1) | $(304.2) | | Net cash provided by (used in) financing activities | $(51.2) | $151.7 | | Net increase (decrease) in cash | $1.0 | $(148.3) | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section details Bruker's business segments, acquisition updates, goodwill, legal contingencies, and a subsequent acquisition of RECIPE Chemicals + Instruments GmbH - The company operates through four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST)[21](index=21&type=chunk) - No acquisitions were completed in the first three months of 2025, with the report providing final valuation details for 2024 acquisitions of Chemspeed, and provisional details for NanoString and ELITechGroup[27](index=27&type=chunk)[34](index=34&type=chunk)[35](index=35&type=chunk) - Goodwill increased slightly to **$1.53 billion** as of March 31, 2025, primarily due to foreign currency effects[50](index=50&type=chunk) - The company is involved in significant patent litigation matters inherited from its acquisitions of PhenomeX (vs AbCellera) and NanoString (vs 10x Genomics), with the accrual for legal matters being **$96.4 million** as of March 31, 2025[98](index=98&type=chunk)[100](index=100&type=chunk)[101](index=101&type=chunk) - Subsequent to the quarter end, on April 14, 2025, the company acquired a **69.6% stake** in RECIPE Chemicals + Instruments GmbH for approximately **$65.3 million**[112](index=112&type=chunk) [Management's Discussion and Analysis (MD&A)](index=30&type=section&id=Item%202%3A%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2025 revenue growth and operating income decline due to acquisition and litigation costs, highlighting improved operating cash flow and liquidity [Results of Operations](index=33&type=section&id=Results%20of%20Operations) Revenue for Q1 2025 grew 11.0% to $801.4 million, with BSI CALID and BSI BioSpin segments showing strong growth largely due to 2024 acquisitions, but operating income fell to $31.8 million from $64.8 million YoY, pressured by increased SG&A, R&D, and a significant jump in 'Other charges, net' Revenue by Segment (in millions) | Segment | Q1 2025 Revenue | Q1 2024 Revenue | % Change | | :--- | :--- | :--- | :--- | | BSI BioSpin | $207.8 | $182.8 | 13.7% | | BSI CALID | $280.1 | $227.9 | 22.9% | | BSI NANO | $256.6 | $240.4 | 6.7% | | BEST | $59.3 | $73.1 | (18.9)% | | **Total** | **$801.4** | **$721.7** | **11.0%** | - The increase in 'Other charges, net' to **$36.9 million** was primarily due to **$18.6 million** of acquisition-related litigation charges (related to BCA and NanoString), **$7.6 million** in restructuring charges, and **$2.1 million** in other acquisition-related expenses[141](index=141&type=chunk) - The effective tax rate increased to **34.7%** from **27.7%** in the prior year, mainly due to changes in jurisdictional mix and the impact of Pillar 2 global minimum tax rules, which added **2.1%** to the rate[146](index=146&type=chunk)[147](index=147&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) The company anticipates existing cash and credit facilities are sufficient for the next twelve months, with net cash from operations at $65.0 million, total debt at $2.1 billion, and access to a $900.0 million revolving credit facility, while repurchasing $10.0 million of common stock during the quarter - The company believes existing cash and credit facilities are sufficient to support operating and investing needs for at least the next twelve months[148](index=148&type=chunk) Key Cash Flow Data (in millions) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $65.0 | $21.8 | | Net cash used in investing activities | $(26.1) | $(304.2) | | Net cash provided by (used in) financing activities | $(51.2) | $151.7 | - During Q1 2025, the company repurchased **200,731 shares** for **$10.0 million** under its share repurchase program, with no shares repurchased in Q1 2024[154](index=154&type=chunk) - As of March 31, 2025, the company had total outstanding debt of **$2.1 billion** and a revolving credit facility providing up to **$900.0 million** in backup liquidity[155](index=155&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203%3A%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) There were no material changes in the company's exposure to market risk from December 31, 2024, except for newly identified tariff risks, as a new universal 10% baseline tariff on all U.S. imports, announced on April 2, 2025, is expected to increase the company's cost of goods sold - A new universal baseline tariff of **10%** on all U.S. imports, announced on April 2, 2025, is expected to increase the company's costs of goods sold[159](index=159&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204%3A%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of March 31, 2025, with no material changes in internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of March 31, 2025[160](index=160&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[162](index=162&type=chunk) Part II [Legal Proceedings](index=39&type=section&id=Item%201%3A%20Legal%20Proceedings) The company is involved in various legal proceedings arising in the ordinary course of business, with material pending legal matters disclosed in Note 20 of the financial statements, detailing significant patent litigation, and is also subject to governmental investigations from time to time - Other than matters disclosed in Note 20 (Commitments and Contingencies), the company is not party to any material pending legal proceedings outside the ordinary course of business[163](index=163&type=chunk) [Risk Factors](index=39&type=section&id=Item%201A%3A%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2024 - The report refers to the risk factors discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, indicating no material changes[165](index=165&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202%3A%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During the first quarter of 2025, the company repurchased 200,731 shares of its common stock at an average price of $49.81 per share, for a total cost of approximately $10.0 million, with approximately $359.9 million remaining available for future repurchases under the authorized program as of March 31, 2025 Share Repurchase Activity for Q1 2025 | Period | Total Shares Purchased | Average Price Paid | Total Cost (approx.) | | :--- | :--- | :--- | :--- | | Jan 2025 | 0 | $— | $0 | | Feb 2025 | 200,731 | $49.81 | $10.0M | | Mar 2025 | 0 | $— | $0 | | **Total Q1** | **200,731** | **$49.81** | **$10.0M** | - As of the end of the quarter, **$359.9 million** remained available for repurchase under the 2023 Repurchase Program, which authorizes up to **$500.0 million** in buybacks over a two-year period[167](index=167&type=chunk)[168](index=168&type=chunk) [Other Information](index=40&type=section&id=Item%205%3A%20Other%20Information) On February 18, 2025, Dr. Cynthia Friend, a member of the Board of Directors, adopted a Rule 10b5-1 trading plan for the potential sale of company shares underlying her equity awards, set to terminate by December 15, 2025, or when all shares under the plan are sold - On February 18, 2025, Director Dr. Cynthia Friend adopted a Rule 10b5-1 trading plan to sell up to **5,192 shares** from vested RSUs and **4,300 shares** from stock options[169](index=169&type=chunk) [Exhibits](index=41&type=section&id=Item%206%3A%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications as required by the Sarbanes-Oxley Act (Sections 302 and 906) and the Inline XBRL financial data files - Exhibits filed include CEO/CFO certifications (31.1, 31.2, 32.1) and Inline XBRL documents (101 series)[171](index=171&type=chunk)

Financial Data and Key Metrics Changes - Bruker reported revenues increased by 11% year over year to $801.4 million, exceeding the preannounced range of $795 million to $800 million [11][36] - Constant exchange rate (CER) revenue growth was 12.5% year over year, with organic growth of 2.9% [11][36] - Non-GAAP operating margin was 12.7%, down year over year due to expected M&A dilution from strategic acquisitions [11][39] - Non-GAAP diluted EPS was $0.47, down from $0.53 in Q1 2024, primarily due to foreign exchange headwinds [12][39] Business Line Data and Key Metrics Changes - BioSpin revenue was $208 million with mid-teens percentage CER growth, driven by strong biopharma performance [12] - CALID group had revenue of €280 million with mid-20s percentage CER growth, led by microbiology and infection diagnostics [13] - Bruker Nano revenue was $257 million with high single-digit percentage CER growth, supported by inorganic revenue growth from NanoString [14] - BEST segment CER revenues declined in the high teens percentage due to weaker performance in the Research Instruments business [14] Market Data and Key Metrics Changes - Americas revenue declined in the low single digits percentage, while European revenue grew in the mid single digits percentage [37] - Asia Pacific revenue grew in the low single digits percentage despite a 10% decline in China [37] - EMEA region revenue was up mid-teens percentage [37] Company Strategy and Development Direction - Bruker launched innovative products in spatial biology, cellular analysis, NMR, microbiology, and molecular diagnostics, enhancing its strategic focus [9] - The company anticipates that post-genomic innovations will drive continued higher revenue CAGR differentiation beyond current headwinds in the U.S. and China [9] - Management is implementing cost initiatives, new pricing actions, and supply chain reengineering to mitigate headwinds from U.S. policy changes and tariffs [20][32] Management's Comments on Operating Environment and Future Outlook - Management expects U.S. academic government revenue to decline by 20% to 25% due to research funding policy changes [24] - The company anticipates a gross headwind of approximately €100 million to organic revenues in fiscal year 2025 from recent policy changes and tariffs [21] - Management remains optimistic about transforming Bruker's portfolio for above-market revenue growth and margin expansion once headwinds abate [46] Other Important Information - The company generated $65 million of operating cash flow in Q1 2025, with free cash flow of $39 million [40] - Updated fiscal year 2025 revenue guidance is $3.48 billion to $3.55 billion, reflecting reported growth of 3.5% to 5.5% [41] - Non-GAAP EPS guidance for 2025 is in the range of $2.40 to $2.48, translating to roughly 0% to 3% growth compared to 2024 [43] Q&A Session Summary Question: Was there any pull forward in the quarter due to tariffs? - Management indicated there was no significant pull forward due to tariffs, although a smooth installation helped Q1 slightly [51][53] Question: How are offsets from AI chips and funding initiatives being considered? - Management noted strong demand for AI tools and potential benefits from German and Korean stimulus funding, but these are expected to have a more significant impact in 2026 and beyond [59][62] Question: How will Bruker offset potential U.S. budget cuts next year? - Management highlighted various growth drivers, including biopharma and European investments, while acknowledging the need to navigate current headwinds [70][72] Question: What is the current state of the order book and backlog? - Management reported a slight decline in the order book year over year, with a backlog of approximately seven months, indicating a buffer for future quarters [78][79] Question: Can you elaborate on pricing and manufacturing initiatives to offset tariffs? - Management is implementing pricing actions and exploring onshoring production to mitigate tariff impacts, with significant cost actions already underway [85][90]

Financial Data and Key Metrics Changes - Bruker's Q1 2025 reported revenues increased 11% year over year to $801.4 million, exceeding the preannounced range of $795 million to $800 million [9][33] - Non-GAAP operating margin for Q1 2025 was 12.7%, down year over year due to expected M&A dilution from strategic acquisitions [9][35] - Diluted non-GAAP EPS for Q1 2025 was $0.47, down from $0.53 in Q1 2024, primarily due to FX currency headwinds [10][36] Business Line Data and Key Metrics Changes - BioSpin revenue was $208 million with mid-teens percentage CER growth, driven by strong biopharma performance [10] - CALID group had revenue of €280 million with mid-20s percentage CER growth, led by microbiology and infection diagnostics [11] - Bruker Nano revenue was $257 million with high single-digit percentage CER growth, supported by inorganic revenue growth from NanoString [12] Market Data and Key Metrics Changes - Americas revenue declined in the low single digits, while European revenue grew in the mid single digits, and Asia Pacific revenue grew in the low single digits despite a 10% decline in China [34] - EMEA region revenue was up mid-teens percentage, indicating strong performance in that market [34] Company Strategy and Development Direction - The company launched innovative products in spatial biology, cellular analysis, NMR, microbiology, and molecular diagnostics, aiming to strengthen high-value offerings [7] - Bruker anticipates that post-genomic innovations will drive continued higher revenue CAGR differentiation beyond current headwinds in the U.S. and China [7] - The company is implementing cost initiatives, new pricing actions, and supply network reengineering to mitigate headwinds from U.S. policy changes and tariffs [29][30] Management's Comments on Operating Environment and Future Outlook - Management expects U.S. academic government revenue to decline by 20% to 25% in 2025 due to funding uncertainties [22][23] - The company anticipates a gross headwind of approximately €100 million to organic revenues in 2025 from policy changes and tariffs [19] - Management remains optimistic about long-term growth, expecting to resume margin expansion and strong EPS growth in 2026 and beyond [42] Other Important Information - The company generated $65 million of operating cash flow in Q1 2025, with free cash flow of $39 million reflecting improved working capital performance [37] - Updated guidance for fiscal year 2025 includes reported revenues of $3.48 billion to $3.55 billion, representing growth of 3.5% to 5.5% [38] Q&A Session Summary Question: Was there any pull forward in the quarter due to tariffs? - Management indicated there was no significant pull forward due to tariffs, although a smooth installation contributed positively to Q1 [49][50] Question: How does the company plan to offset potential budget cuts in the U.S.? - Management highlighted several growth drivers, including biopharma, AI, and European defense spending, which could help offset budget cuts [66][68] Question: What is the current status of the order book and backlog? - The order book was slightly down year over year, but the backlog remains strong at around seven months, providing a buffer for future quarters [73][104]

Financial Performance - Bruker's Q1 2025 revenues increased by $79.7 million, representing an 11% growth compared to Q1 2024[6] - The company's constant-exchange rate (CER) growth was +12.5%[6] - Organic revenue change increased by +2.9%, with Bruker Scientific Instruments (BSI) up +5.1% and Bruker Energy & Supercon Technologies (BEST) down -17.7%[6] - Acquisitions contributed +9.6% to revenue growth, while foreign exchange (FX) had a -1.5% headwind[6] - Non-GAAP EPS decreased by -11.3% to $0.47, compared to $0.53 in Q1 2024[6] Segment Performance - Bruker BIOSPIN Group experienced mid-teens % CER revenue growth, driven by preclinical imaging and lab automation[12] - Bruker CALID Group saw mid-20s % CER revenue growth, with strong performance in Life Science Mass Spectrometry and Microbiology & Infection Diagnostics[12] - Bruker NANO Group's CER revenue increased by high single digits %, aided by NanoString acquisition[18] - Bruker Energy & Supercon Technologies (BEST) segment experienced a high teens % decline in CER revenue, primarily due to softness in superconductors for clinical MRI[18] Financial Outlook - The company projects FY 2025 revenue between $3.48 billion and $3.55 billion, representing a reported revenue growth of +3.5% to +5.5%[45] - Organic revenue growth for FY 2025 is expected to be between +0% and +2%[45] - Non-GAAP EPS for FY 2025 is projected to be between $2.40 and $2.48, with a reported EPS growth of +0% to +3%[45]

Core Insights - Solis Agrosciences has appointed Crystal Winkeler as Chief Business Officer to enhance its commercial team and drive growth initiatives [1][2] - Winkeler brings extensive experience from her previous roles, including leading investments at BioGenerator Ventures and co-founding Canopy Biosciences [2][3] - The company has shown significant progress in the AgTech sector, expanding its management team and launching new product offerings [6] Company Developments - Solis Agrosciences has secured a license for the Pairwise Fulcrum™ Platform and entered the whole-genome-sequencing market through the acquisition of Ferris Genomics [6] - The company has attracted new investments from Cultivation Capital and has significantly increased its sales [6] - Solis operates within the 39 North AgTech Innovation District in St. Louis, Missouri, focusing on high-quality AgTech research services [8][10] Leadership and Expertise - Crystal Winkeler is recognized for her ability to build business relationships and her scientific expertise, which will be beneficial for Solis [2][3] - Winkeler has a Ph.D. in Molecular Cell Biology from Washington University, adding to her qualifications [5] - Previous leadership roles include managing a team of over 40 at Canopy Biosciences and leading due diligence for seed investments at BioGenerator Ventures [3][4] Investment Landscape - Major investors in Solis include Hermann Companies, Cultivation Capital, and BioGenerator Ventures, among others [7] - Cultivation Capital is noted for being an active early-stage venture capital firm, having invested in over 150 companies since its inception [9]

| 供应商名称 | 供应商地址 | 供应商联系电 | 中标（成交）金额 | | --- | --- | --- | --- | | | | 话 | (元) | | 陕西文投国际贸易有 | 西安国际港务区新丝路国际电商产业 | 029- | 17600000.00 | | 限公司 | 园B座10层1002-4室 | 81777596 | | 四、主要标的信息 | 序号 | 产品名称 | 品牌、规格型号 | 制造商 | 单价(元) | 数量 | 总价(元) | | --- | --- | --- | --- | --- | --- | --- | | | 核磁共振波谱仪 | 布鲁克、AVANCENEO 600 | 布鲁克瑞士有限公司 | 6970000. 00 | 1 套 | 6970000.00 | | 2 | X 射线精细结构谱仪 | 安徽创谱、Table XAFS- 3000 | 安徽创谱仪器科技有限 公司 | 4000000. 00 | 1 套 | 4000000.00 | | 3 | 场发射电子探针显微镜 | 日本岛津、EPMA-8050G | 岛津制作所 | 6630000. 00 | 1 套 | 6 ...